Biogen Inc

Biogen’s FDA‑approved lecanemab autoinjector and litifilimab breakthrough marks a major advance for Alzheimer’s and lupus treatment, boosting investor confidence and positioning the biotech firm for future growth.

Institutional buying backs Biogen’s growth—Goldman Sachs, Bridgewater and more lift confidence in its neurology, oncology pipeline and steady sales, hinting at future upside.

Biogen has secured a comprehensive licensing deal with Vanqua Bio for a preclinical C5aR1 antagonist, potentially worth up to $1.06 billion, marking a strategic expansion of its immunology pipeline and a bold move into new market segments.

Biogen Inc. has updated its financial guidance, citing strong sales of its Alzheimer’s drug, and reported promising results from ongoing studies, solidifying its position as a key player in the biotechnology sector.

Biogen Inc. has initiated a global Phase 3 clinical study, PROMINENT, to evaluate the efficacy and safety of felzartamab in treating primary membranous nephropathy, a rare kidney disease.

Biogen Inc.’s stock price has declined significantly from its 52-week high of $238 to $126.30, reflecting broader market dynamics and investor sentiment.

Biogen Inc. reported strong Q1 2025 performance with $2.43 billion in revenue, driven by demand for its rare disease therapies, despite lowering its full-year earnings guidance.